期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 24, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/ijms24065722
关键词
aspartylglucosaminuria; lysosomal storage disorders; biomarkers; protein glycosylation; enzymes
Novel treatment strategies for rare genetic diseases require reliable biomarkers to assess treatment effect. In this study, a validated fluorometric AGA activity assay was established for assessing AGA activity in human serum samples. The assay proved to be suitable for diagnosing AGU and potentially monitoring treatment effect.
Novel treatment strategies are emerging for rare, genetic diseases, resulting in clinical trials that require adequate biomarkers for the assessment of the treatment effect. For enzyme defects, biomarkers that can be assessed from patient serum, such as enzyme activity, are highly useful, but the activity assays need to be properly validated to ensure a precise, quantitative measurement. Aspartylglucosaminuria (AGU) is a lysosomal storage disorder caused by the deficiency of the lysosomal hydrolase aspartylglucosaminidase (AGA). We have here established and validated a fluorometric AGA activity assay for human serum samples from healthy donors and AGU patients. We show that the validated AGA activity assay is suitable for the assessment of AGA activity in the serum of healthy donors and AGU patients, and it can be used for diagnostics of AGU and, potentially, for following a treatment effect.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据